{
    "name": "Factor XIII A-subunit, recombinant",
    "comment": "Rx",
    "other_names": [
        "Tretten",
        "catridecacog"
    ],
    "classes": [
        "Coagulation Factors",
        "Hemostatics"
    ],
    "source": "https://reference.medscape.com/drug/tretten-factor-xiii-a-subunit-recombinant-999910",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Unknown if distributed in human breast milk"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Unknown if distributed in human breast milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Allergic reactions reported, including urticaria, rash, chest tightness, wheezing, and hypotension; if these symptoms occur, discontinue immediately and institute appropriate treatment",
                "Thromboembolic complications reported; monitor patients with predisposing conditions for thrombosis",
                "Coadministration with Factor VIIa may cause thrombosis",
                "Inhibitory antibodies may occur and result in inadequate response to treatment; if expected plasma FXIII activity levels are not attained, or if breakthrough bleeding occurs while receiving prophylaxis, perform an assay that measures FXIII inhibitory antibody concentrations"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "Factor VIIa, recombinant",
            "description": {
                "common": "Factor VIIa, recombinant, Factor XIII A-subunit, recombinant.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Thrombosis occurred in preclinical trials when excessive FXIII doses were coadministered with FVIIa."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Extremity pain",
            "percent": null
        },
        {
            "name": "Injection site pain",
            "percent": null
        },
        {
            "name": "Increased fibrin D dimer levels",
            "percent": null
        },
        {
            "name": "Antibody formation",
            "percent": null
        }
    ]
}